Long-term follow up of glatiramer acetate compassionate use in Belgium

Acta Neurologica Belgica

Volumn 105, Issue 2, 2005, Pages 81-85

  Sindic, C J M ^a   Seeldrayers, P ^b   Vande Gaer, L ^c   De Smet, E ^c   Nagels, G ^d   De Deyn, P P ^d   Medaer, R ^e   Guillaume, D ^f   D'Hooghe, M B ^g   Deville, M C ^g   Decoo, D ^h   Sadzot, B ⁱ   Van Landegem, W ^j   Strauven, T ^j   Pepin, J ^k   Merckx, H ^l   Caekebeke, J ^m   van der Tool, M A ⁿ  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c MS and Revalidatie Centrum Overpelt

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e MS and Revalidatie Centrum Hasselt   (Belgium)

^f Centre Neurol and Réadaptation Fraiture

^g MS Centrum Melsbroek   (Belgium)

^h Elisabeth Ziekenhuis Sijsele   (Belgium)

ⁱ UNIVERSITY OF LIÈGE   (Belgium)

^j SINT AUGUSTINUS HOSPITAL   (Belgium)

^k Centre Hospitalier Regional de La Citadelle   (Belgium)

^l Algemeen Ziekenhuis Menen   (Belgium)

^m OLV HOSPITAL   (Belgium)

ⁿ Teva Pharma Bv Haarlem N1   (Netherlands)

more..

Author keywords

Disease modifying drugs; Glatiramer acetate and long term follow up; Multiple sclerosis

Indexed keywords

GLATIRAMER;

ADULT; ARTICLE; ASTHMA; BELGIUM; CLINICAL PROTOCOL; CYST; DEPRESSION; DISABILITY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FLUSHING; FOLLOW UP; HEADACHE; HEALTH STATUS; HEALTH SURVEY; HUMAN; INFECTION; INJECTION SITE REACTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MOBILIZATION; MULTIPLE SCLEROSIS; MUSCLE SPASM; RELAPSE; REMISSION; SIDE EFFECT; SWEATING;

EID: 22144498485     PISSN: 03009009     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Comi G., Filippi M., Wolinsky J. S., and the European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann. Neurol., 2001, 49: 290-297.
2. Johnson K. P., Brooks B. R., Cohen J. A., Ford C. C., Goldstein J. et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology, 1995, 45: 1268-1276.
3. Johnson K. P., Brooks B. R., Cohen J. A., Ford C. C., Goldstein J. et al. Extended use of glatiramer acetate (Copaxone®) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology, 1998, 50: 701-708.
4. Johnson K. P., Brooks B. R., Ford C. C., Goodman A., Guarnaccia J. et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult. Scler., 2000, 6 (4): 255-266.
5. Miller A., Shapiro S., Gershtein R., Kinarty A., Rawashdeh H. et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone®): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J. Neuroimmunol., 1998, 92: 113-121.
6. Neuhaus O., Farina C., Wekerlen H., Hohlfeld R. et al. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology, 2001, 56: 702-708.
7. Weinshenker B. G., Rice G., Noseworthy J. H., Carriere W., Baskerville J. et al. The natural history of Multiple Sclerosis: A geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain, 1991, 114: 1045-1056.
8. Wolinsky J. S., Narayana P. A., Johnson K. P. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. Mult. Scler., 2001, 7: 33-41.
9. Wolinsky J. S., Comi G., Filippi M., Ladkani D., Kadosh S. et al. Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained. Neurology, 2002, 59: 1284-1286.
10. Teitelbaum D., Webb C., Bree M., Meshorer A., Arnon R. et al. Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymer. Clin. Immunol. Immunopathol., 1974, 3: 256-262.
11. Ziemssen T., Neuhaus O., Hohlfeld R. et al. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Safety, 2001, 24: 979-990.